Vivek Subbiah: F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer
oncodaily - Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Wow! It’s Big news on Friday. F.D.A. Grants Early Access to Promising Drug for […]
AI Summary: The FDA has authorized early access to a promising experimental therapy for pancreatic cancer, opening an expanded‑access pathway so eligible patients can receive the drug before full approval. Regulators based the decision on encouraging early clinical signals of activity and manageable safety data, aiming to offer options for a disease with few effective treatments—because pancreatic cancer isn’t known for its patience.
#healthcare #pharmaceuticals #biotech #drugdevelopment #fda #oncology #pancreaticcancer #cancerresearch #clinicaltrials
- Daraxonrasib expanded access: FDA opens early pathway (6)
- Research advances: diagnostics and targeted therapies for pancreatic cancer (5)
- All Other Stories